Mammary Tumor Cells with High Metastatic Potential Are Hypersensitive to Macrophage-Derived HGF.
Takanori KitamuraYu KatoDemi BrownlieDaniel Y H SoongGaël SuganoNicolle KippenJiufeng LiDahlia Doughty-ShentonNeil CarragherJeffery W PollardPublished in: Cancer immunology research (2019)
Metastasis-associated macrophages (MAM) promote persistent growth of breast cancer cells at the metastatic site and are, thus, an attractive therapeutic target to treat breast cancer metastasis, a leading cause of cancer-related death in women. However, the precise mechanisms behind MAM-mediated metastatic tumor outgrowth have not been fully elucidated. Using mouse models of metastatic breast cancer, we showed that MAMs uniquely expressed hepatocyte growth factor (HGF) in metastatic tumors. We also demonstrated that a selected population of cancer cells with high metastatic potential (cancer cells that can establish metastatic tumors in mice with higher number and incidence than parental cells) had higher expression of HGF receptor, MNNG HOS transforming gene (MET), and were more responsive to HGF released from macrophages compared with the parental cells. Blockade of MET signaling in cancer cells suppressed metastatic tumor expansion, in part, through activation of natural killer cells. Results from this study suggest an approach to prevent life-threatening metastatic tumor formation using blockade of MAM-induced MET signal activation in metastatic cancer cells.
Keyphrases
- squamous cell carcinoma
- small cell lung cancer
- growth factor
- induced apoptosis
- metastatic breast cancer
- mouse model
- type diabetes
- gene expression
- poor prognosis
- pregnant women
- breast cancer cells
- skeletal muscle
- cell proliferation
- risk factors
- copy number
- genome wide
- polycystic ovary syndrome
- young adults
- climate change
- long non coding rna
- stress induced
- childhood cancer